Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.190
-0.020 (-1.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.190
0.00 (0.00%)
Pre-market: Apr 29, 2026, 5:11 AM EDT
Actinium Pharmaceuticals Revenue
In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K.
Revenue (ttm)
$90.00K
Revenue Growth
n/a
P/S Ratio
412.22
Revenue / Employee
$3,600
Employees
25
Market Cap
37.10M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Cue Biopharma | 27.47M |
| Veru Inc. | 16.89M |
| Evaxion | 7.53M |
| CervoMed | 4.01M |
| Aligos Therapeutics | 2.19M |
| Pluri | 1.34M |
| Werewolf Therapeutics | 1.14M |
ATNM News
- 7 days ago - Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 7 days ago - Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 14 days ago - NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225 - Business Wire
- 23 days ago - Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PRNewsWire
- 2 months ago - BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - Business Wire
- 4 months ago - Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 - PRNewsWire
- 5 months ago - Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium - PRNewsWire
- 5 months ago - The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - Newsfile Corp